PubRank

Anne-Mieke Vandamme

Author PubWeight™ 176.43‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009 8.37
2 An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 2005 5.60
3 The molecular population genetics of HIV-1 group O. Genetics 2004 4.53
4 Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis 2007 3.80
5 Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005 3.52
6 Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2005 3.17
7 U.S. Human immunodeficiency virus type 1 epidemic: date of origin, population history, and characterization of early strains. J Virol 2003 2.64
8 Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 2009 2.60
9 Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event. J Virol 2005 2.35
10 Tracing the origin and history of the HIV-2 epidemic. Proc Natl Acad Sci U S A 2003 2.31
11 A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences. Nucleic Acids Res 2009 2.06
12 Characterization of a novel simian immunodeficiency virus with a vpu gene from greater spot-nosed monkeys (Cercopithecus nictitans) provides new insights into simian/human immunodeficiency virus phylogeny. J Virol 2002 1.99
13 A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients. Antivir Ther 2002 1.92
14 Prevalence and correlates of nonadherence to antiretroviral therapy in a population of HIV patients using Medication Event Monitoring System. AIDS Patient Care STDS 2004 1.75
15 Recombination confounds the early evolutionary history of human immunodeficiency virus type 1: subtype G is a circulating recombinant form. J Virol 2007 1.74
16 Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: performance evaluation of the new REGA version 3 and seven other tools. Infect Genet Evol 2013 1.69
17 Genetic variability and molecular evolution of the human respiratory syncytial virus subgroup B attachment G protein. J Virol 2005 1.60
18 DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS One 2010 1.59
19 Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach. Retrovirology 2009 1.58
20 Phylogenetic surveillance of viral genetic diversity and the evolving molecular epidemiology of human immunodeficiency virus type 1. J Virol 2007 1.57
21 Diagnostic value of different adherence measures using electronic monitoring and virologic failure as reference standards. AIDS Patient Care STDS 2008 1.54
22 A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. Proc Natl Acad Sci U S A 2002 1.53
23 Quantifying differences in the tempo of human immunodeficiency virus type 1 subtype evolution. J Virol 2009 1.49
24 Relating increasing hantavirus incidences to the changing climate: the mast connection. Int J Health Geogr 2009 1.48
25 Molecular evolution and circulation patterns of human respiratory syncytial virus subgroup a: positively selected sites in the attachment g glycoprotein. J Virol 2004 1.48
26 Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G. AIDS 2005 1.41
27 The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal. Retrovirology 2008 1.38
28 Hepatitis C virus evolutionary patterns studied through analysis of full-genome sequences. J Mol Evol 2002 1.38
29 HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms. J Acquir Immune Defic Syndr 2003 1.38
30 Molecular footprint of drug-selective pressure in a human immunodeficiency virus transmission chain. J Virol 2005 1.36
31 Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. PLoS One 2010 1.33
32 Use of electronic monitoring induces a 40-day intervention effect in HIV patients. J Acquir Immune Defic Syndr 2006 1.33
33 HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics. Retrovirology 2013 1.30
34 The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr 2006 1.27
35 Analysis of the serotype and genotype correlation of VP1 and the 5' noncoding region in an epidemiological survey of the human enterovirus B species. J Clin Microbiol 2004 1.22
36 Investigation of expert rule bases, logistic regression, and non-linear machine learning techniques for predicting response to antiretroviral treatment. Antivir Ther 2009 1.20
37 Identification in gelada baboons (Theropithecus gelada) of a distinct simian T-cell lymphotropic virus type 3 with a broad range of Western blot reactivity. J Gen Virol 2004 1.18
38 Rising prevalence of HIV-1 non-B subtypes in Belgium: 1983-2001. J Acquir Immune Defic Syndr 2004 1.17
39 Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins. J Virol 2004 1.17
40 Limitations to contact tracing and phylogenetic analysis in establishing HIV type 1 transmission networks in Cuba. AIDS Res Hum Retroviruses 2007 1.16
41 Mapping sites of positive selection and amino acid diversification in the HIV genome: an alternative approach to vaccine design? Genetics 2004 1.15
42 Assessment of automated genotyping protocols as tools for surveillance of HIV-1 genetic diversity. AIDS 2006 1.14
43 Different epidemic potentials of the HIV-1B and C subtypes. J Mol Evol 2005 1.12
44 Tenofovir resistance and resensitization. Antimicrob Agents Chemother 2003 1.10
45 A genotypic resistance assay for the detection of drug resistance in the human immunodeficiency virus type 1 envelope gene. J Virol Methods 2005 1.10
46 Phylodynamics of the HIV-1 CRF02_AG clade in Cameroon. Infect Genet Evol 2011 1.10
47 In vivo characteristics of human immunodeficiency virus type 1 intersubtype recombination: determination of hot spots and correlation with sequence similarity. J Gen Virol 2003 1.09
48 Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob Agents Chemother 2006 1.08
49 Antiretroviral resistance in different HIV-1 subtypes: impact on therapy outcomes and resistance testing interpretation. Curr Opin HIV AIDS 2007 1.06
50 env chimeric virus technology for evaluating human immunodeficiency virus susceptibility to entry inhibitors. Antimicrob Agents Chemother 2002 1.04
51 No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: impact of resistant minority variants on efficacy of low genetic barrier drugs. J Clin Virol 2007 1.03
52 Phylogenetic reconstruction of a known HIV-1 CRF04_cpx transmission network using maximum likelihood and Bayesian methods. J Mol Evol 2004 1.03
53 Phylogeographical footprint of colonial history in the global dispersal of human immunodeficiency virus type 2 group A. J Gen Virol 2011 1.03
54 Mosaic genomes of the six major primate lentivirus lineages revealed by phylogenetic analyses. J Virol 2003 1.03
55 High GUD incidence in the early 20 century created a particularly permissive time window for the origin and initial spread of epidemic HIV strains. PLoS One 2010 1.03
56 Complete genome sequence, taxonomic assignment, and comparative analysis of the untranslated regions of the Modoc virus, a flavivirus with no known vector. Virology 2002 1.02
57 Phylogeny of primate T lymphotropic virus type 1 (PTLV-1) including various new Asian and African non-human primate strains. Infect Genet Evol 2006 1.02
58 Limited cross-border infections in patients newly diagnosed with HIV in Europe. Retrovirology 2013 1.01
59 Functional conservation of HIV-1 Gag: implications for rational drug design. Retrovirology 2013 1.01
60 A Bayesian statistical analysis of human T-cell lymphotropic virus evolutionary rates. Infect Genet Evol 2004 1.01
61 Predictive value of HIV-1 genotypic resistance test interpretation algorithms. J Infect Dis 2009 1.00
62 Gender differences in HIV disease progression and treatment outcomes among HIV patients one year after starting antiretroviral treatment (ART) in Dar es Salaam, Tanzania. BMC Public Health 2013 1.00
63 Performance of ViroSeq HIV-1 Genotyping System in routine practice at a Belgian clinical laboratory. J Virol Methods 2004 0.99
64 Early sequential development of infective dermatitis, human T cell lymphotropic virus type 1-associated myelopathy, and adult T cell leukemia/lymphoma. Clin Infect Dis 2008 0.99
65 Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based models. PLoS One 2010 0.98
66 Algorithms for the interpretation of HIV-1 genotypic drug resistance information. Antiviral Res 2006 0.97
67 Genotypic drug resistance interpretation algorithms display high levels of discordance when applied to non-B strains from HIV-1 naive and treated patients. FEMS Immunol Med Microbiol 2006 0.97
68 Circulation of genetically distinct contemporary human coronavirus OC43 strains. Virology 2005 0.97
69 Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG. Antivir Ther 2006 0.97
70 HIV-1 compartmentalization in diverse leukocyte populations during antiretroviral therapy. J Leukoc Biol 2004 0.96
71 Pharmacy refill adherence outperforms self-reported methods in predicting HIV therapy outcome in resource-limited settings. BMC Public Health 2014 0.96
72 The rise and fall of K65R in a Portuguese HIV-1 Drug Resistance database, despite continuously increasing use of tenofovir. Infect Genet Evol 2008 0.96
73 Molecular testing of multiple HIV-1 transmissions in a criminal case. AIDS 2005 0.96
74 Human retroviruses (HIV and HTLV) in Brazilian Indians: seroepidemiological study and molecular epidemiology of HTLV type 2 isolates. AIDS Res Hum Retroviruses 2002 0.96
75 Estimating the relative contribution of dNTP pool imbalance and APOBEC3G/3F editing to HIV evolution in vivo. J Comput Biol 2007 0.95
76 Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. J Infect Dis 2013 0.94
77 Comparative performance of the REGA subtyping tool version 2 versus version 1. Infect Genet Evol 2009 0.94
78 Bayesian network analyses of resistance pathways against efavirenz and nevirapine. AIDS 2008 0.94
79 An integrated map of HIV genome-wide variation from a population perspective. Retrovirology 2015 0.93
80 RegaDB: community-driven data management and analysis for infectious diseases. Bioinformatics 2013 0.93
81 Antiretroviral drug resistance in HIV-1 therapy-naive patients in Cuba. Infect Genet Evol 2013 0.93
82 Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006. AIDS Res Hum Retroviruses 2008 0.92
83 Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients. Retrovirology 2012 0.91
84 Development and validation of a multiplex real-time PCR assay for simultaneous genotyping and human T-lymphotropic virus type 1, 2, and 3 proviral load determination. J Clin Microbiol 2009 0.91
85 Assessing transmissibility of HIV-1 drug resistance mutations from treated and from drug-naive individuals. AIDS 2015 0.90
86 Prevalence of antiretroviral drug resistance mutations and HIV-1 non-B subtypes in newly diagnosed drug-naïve patients in Slovenia, 2000-2004. Virus Res 2006 0.90
87 Full-genome analysis of a highly divergent simian T-cell lymphotropic virus type 1 strain in Macaca arctoides. J Gen Virol 2005 0.90
88 A genotypic assay for the amplification and sequencing of gag and protease from diverse human immunodeficiency virus type 1 group M subtypes. J Virol Methods 2005 0.90
89 A public HTLV-1 molecular epidemiology database for sequence management and data mining. PLoS One 2012 0.89
90 Impact on replicative fitness of the G48E substitution in the protease of HIV-1: an in vitro and in silico evaluation. J Acquir Immune Defic Syndr 2008 0.89
91 Interpreting resistance data for HIV-1 therapy management--know the limitations. AIDS Rev 2006 0.88
92 Phylogenetic classification of TT virus groups based on the N22 region is unreliable. Virus Res 2002 0.87
93 Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response. Antivir Ther 2008 0.87
94 Evolutionary dynamics of human retroviruses investigated through full-genome scanning. Mol Biol Evol 2005 0.87
95 Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates. J Antimicrob Chemother 2008 0.86
96 Science in court: the myth of HIV fingerprinting. Lancet Infect Dis 2011 0.85
97 Full-length HIV type 1 genome analysis showing evidence for HIV type 1 transmission from a nonprogressor to two recipients who progressed to AIDS. AIDS Res Hum Retroviruses 2005 0.85
98 Nonadherence to highly active antiretroviral therapy: clinically relevant patient categorization based on electronic event monitoring. AIDS Res Hum Retroviruses 2002 0.84
99 HIV-1 transmitted drug resistance in Latin America and the Caribbean: what do we know? AIDS Rev 2012 0.84
100 Comparison of three ELISAs for the routine diagnosis of human T-lymphotropic virus infection in a high-prevalence setting in Peru. Trans R Soc Trop Med Hyg 2009 0.84
101 Adult T-cell leukemia/lymphoma with a mixed CD4+ and CD8+ phenotype and indolent course. J Clin Oncol 2007 0.84
102 Prevalence and origin of HIV-1 group M subtypes among patients attending a Belgian hospital in 1999. Virus Res 2002 0.84
103 The close relationship between South African and Latin American HTLV type 1 strains corroborated in a molecular epidemiological study of the HTLV type 1 isolates from a blood donor cohort. AIDS Res Hum Retroviruses 2007 0.84
104 Complete genome sequence of Montana Myotis leukoencephalitis virus, phylogenetic analysis and comparative study of the 3' untranslated region of flaviviruses with no known vector. J Gen Virol 2002 0.84
105 Exploring full-genome sequences for phylogenetic support of HIV-1 transmission events. AIDS 2005 0.83
106 Brazilian HTLV type 2a strains from intravenous drug users (IDUs) appear to have originated from two sources: Brazilian Amerindians and European/North American IDUs. AIDS Res Hum Retroviruses 2003 0.83
107 Role of viral evolutionary rate in HIV-1 disease progression in a linked cohort. Retrovirology 2005 0.83
108 High frequency of antiviral drug resistance and non-B subtypes in HIV-1 patients failing antiviral therapy in Cuba. J Clin Virol 2012 0.83
109 HIV-1 protease mutation 82M contributes to phenotypic resistance to protease inhibitors in subtype G. J Antimicrob Chemother 2012 0.83
110 Genetic analyses reveal structured HIV-1 populations in serially sampled T lymphocytes of patients receiving HAART. Virology 2006 0.83
111 Frequent HTLV-1 infection in the offspring of Peruvian women with HTLV-1-associated myelopathy/tropical spastic paraparesis or strongyloidiasis. Rev Panam Salud Publica 2007 0.83
112 Enhanced heterosexual transmission hypothesis for the origin of pandemic HIV-1. Viruses 2012 0.82
113 A genotypic assay for the amplification and sequencing of integrase from diverse HIV-1 group M subtypes. J Virol Methods 2008 0.82
114 Change in hepatitis C virus genotype in hemodialysis patients after end-of-treatment response to interferon monotherapy--relapse or re-infection? J Med Virol 2008 0.82
115 Clinical evaluation of Rega 8: an updated genotypic interpretation system that significantly predicts HIV-therapy response. PLoS One 2013 0.82
116 Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G. J Antimicrob Chemother 2009 0.82
117 Comparative rates of nucleotide sequence variation in the hypervariable region of E1/E2 and the NS5b region of hepatitis C virus in patients with a spectrum of liver disease resulting from a common source of infection. Virology 2002 0.82
118 HIV-1 Gag C-terminal amino acid substitutions emerging under selective pressure of protease inhibitors in patient populations infected with different HIV-1 subtypes. Retrovirology 2014 0.82
119 Cellular HIV-1 DNA levels in drug sensitive strains are equivalent to those in drug resistant strains in newly-diagnosed patients in Europe. PLoS One 2010 0.81
120 Clinical and virological response to antiretroviral drugs among HIV patients on first-line treatment in Dar-es-Salaam, Tanzania. J Infect Dev Ctries 2014 0.81
121 Ascorbic acid has superior ex vivo antiproliferative, cell death-inducing and immunomodulatory effects over IFN-α in HTLV-1-associated myelopathy. PLoS Negl Trop Dis 2012 0.81
122 Multi-science decision support for HIV drug resistance treatment. Stud Health Technol Inform 2008 0.81
123 Globin haplotypes of human T-cell lymphotropic virus type I-infected individuals in Salvador, Bahia, Brazil, suggest a post-Columbian African origin of this virus. J Acquir Immune Defic Syndr 2003 0.81
124 Lack of evidence for infection with simian immunodeficiency virus in bonobos. AIDS Res Hum Retroviruses 2002 0.81
125 A collaborative environment allowing clinical investigations on integrated biomedical databases. Stud Health Technol Inform 2009 0.81
126 Mutations selected in HIV-2-infected patients failing a regimen including atazanavir. J Antimicrob Chemother 2012 0.81
127 Novel recombinant virus assay for measuring susceptibility of human immunodeficiency virus type 1 group M subtypes to clinically approved drugs. J Clin Microbiol 2009 0.80
128 High prevalence of CRF02_AG and many minor resistance-related mutations at the protease gene among HIV-infected treatment-naive immigrants in Madrid. AIDS 2003 0.80
129 Understanding the changing prevalence of K65R. AIDS Rev 2008 0.79
130 Estimating the individualized HIV-1 genetic barrier to resistance using a nelfinavir fitness landscape. BMC Bioinformatics 2010 0.79
131 Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen. J Antimicrob Chemother 2013 0.78
132 Western blot seroindeterminate individuals for human T-lymphotropic virus I/II (HTLV-I/II) in Fortaleza (Brazil): a serological and molecular diagnostic and epidemiological approach. Braz J Infect Dis 2003 0.78
133 Effect of human immunodeficiency virus type 1 protease inhibitor therapy and subtype on development of resistance in subtypes B and G. Infect Genet Evol 2009 0.78
134 Simultaneous RNA quantification of human and retroviral genomes reveals intact interferon signaling in HTLV-1-infected CD4+ T cell lines. Virol J 2012 0.78
135 Mutations at 65 and 70 within the context of a Q151M cluster in human immunodeficiency virus type 1 reverse transcriptase impact the susceptibility to the different nucleoside reverse transcriptase inhibitors in distinct ways. Infect Genet Evol 2007 0.78
136 Disentangling the impact of within-host evolution and transmission dynamics on the tempo of HIV-1 evolution. AIDS 2015 0.78
137 Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort. BMC Infect Dis 2013 0.78
138 CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis. J Neuroinflammation 2014 0.78
139 Correction: Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis. PLoS Med 2015 0.78
140 Evaluation of the automatic editing tool RECall for HIV-1 pol and V3 loop sequences. J Virol Methods 2013 0.77
141 HIV-1 drug resistance: where do polymorphisms fit in? Future Microbiol 2013 0.77
142 Mutations in both env and gag genes are required for HIV-1 resistance to the polysulfonic dendrimer SPL2923, as corroborated by chimeric virus technology. Antivir Chem Chemother 2005 0.77
143 The rare HIV-1 gp41 mutations 43T and 50V elevate enfuvirtide resistance levels of common enfuvirtide resistance mutations that did not impact susceptibility to sifuvirtide. Antiviral Res 2010 0.77
144 The demise of multidrug-resistant HIV-1: the national time trend in Portugal. J Antimicrob Chemother 2012 0.77
145 Current levels of drug resistance among therapy-naive HIV-infected patients have significant impact on treatment response. J Acquir Immune Defic Syndr 2004 0.76
146 Reanalysis of the HIV-1 circulating recombinant form A/E (CRF01_AE): evidence of A/E/G recombination. J Acquir Immune Defic Syndr 2002 0.75
147 Large cluster outbreaks sustain the HIV epidemic among MSM in Quebec. AIDS 2017 0.75
148 Evolution of genotypic resistance to enfuvirtide in HIV-1 isolates from different group M subtypes. J Clin Virol 2009 0.75
149 A rapid phenotypic assay for detecting multiple nucleoside analogue reverse transcriptase inhibitor-resistant HIV-1 in plasma. Antivir Ther 2002 0.75
150 Virologic therapy response significantly correlates with the number of active drugs as evaluated using a LiPA HIV-1 resistance scoring system. J Clin Virol 2004 0.75
151 Appearance of a single amino acid insertion at position 33 in HIV type 1 protease under a lopinavir-containing regimen, associated with reduced protease inhibitor susceptibility. AIDS Res Hum Retroviruses 2011 0.75
152 A combination of poor adherence and a low baseline susceptibility score is highly predictive for HAART failure. Antivir Chem Chemother 2002 0.75
153 HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure. Infect Genet Evol 2013 0.75
154 Viral evolution and molecular epidemiology--evolving viruses and evolving analysis techniques. FEMS Immunol Med Microbiol 2003 0.75
155 International BioInformatics Workshop on Virus Evolution and Molecular Epidemiology. Infect Genet Evol 2013 0.75